Brief: Creative Medical Technology Holdings Completes Amniostem™ Preclinical Studies Needed For FDA Application Filing
09/07/2020 14:01
July 9 (Reuters) - Creative Medical Technology Holdings Inc
CELZ.PK :
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS COMPLETES AMNIOSTEM™
PRECLINICAL STUDIES NEEDED FOR FDA INVESTIGATIONAL NEW DRUG
APPLICATION FILING
Source text for Eikon: ID:nPn33zXMLa
Further company coverage: CELZ.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM